Trexquant Investment LP Buys 13,996 Shares of Insulet Co. (NASDAQ:PODD)

Trexquant Investment LP grew its stake in Insulet Co. (NASDAQ:PODD) by 25.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,045 shares of the medical instruments supplier’s stock after purchasing an additional 13,996 shares during the period. Trexquant Investment LP owned approximately 0.10% of Insulet worth $17,765,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PODD. Integrated Wealth Concepts LLC boosted its stake in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after buying an additional 42 shares during the period. Horizon Investments LLC boosted its stake in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $362,000 after purchasing an additional 42 shares during the period. Nisa Investment Advisors LLC raised its position in Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares during the period. Glenmede Trust Co. NA raised its position in Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares during the period. Finally, Graypoint LLC lifted its stake in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares during the last quarter.

Insulet Stock Performance

PODD stock opened at $263.18 on Wednesday. The firm has a 50-day simple moving average of $271.17 and a two-hundred day simple moving average of $259.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The firm has a market cap of $18.48 billion, a price-to-earnings ratio of 45.45, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. On average, equities analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PODD shares. Piper Sandler raised their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. StockNews.com cut shares of Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Canaccord Genuity Group lifted their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Citigroup upped their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $292.06.

Insider Transactions at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.